Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells

International Journal of Cancer

Volumn 133, Issue 3, 2013, Pages 771-778

  Sisirak, Vanja ^a,b,c,d   Vey, Nelly ^a,b,c,d   Goutagny, Nadège ^a,b,c,d   Renaudineau, Sarah ^a,b,c,d   Malfroy, Marine ^a,b,c,d   Thys, Sandra ^a,b,c,d   Treilleux, Isabelle ^e   Labidi Galy, Sana Intidhar ^a,b,c,d,e   Bachelot, Thomas ^a,b,c,d,e   Dezutter Dambuyant, Colette ^a,b,c,d   Ménétrier Caux, Christine ^a,b,c,d   Blay, Jean Yves ^a,b,c,d,e   Caux, Christophe ^a,b,c,d,e   Bendriss Vermare, Nathalie ^a,b,c,d,e  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^d LabEx DEVweCAN   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

breast cancer; plasmacytoid dendritic cells; TGF ; TLR ligands; type I IFNs

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON REGULATORY FACTOR 7; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; SMAD2 PROTEIN; SMAD3 PROTEIN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOWN REGULATION; HUMAN; IMMUNOFLUORESCENCE; INTERFERON INDUCTION; INTERFERON PRODUCTION; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPERNATANT; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION;

BREAST NEOPLASMS; CHEMOKINE CCL3; CHEMOKINE CXCL10; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON REGULATORY FACTOR-7; INTERFERON-ALPHA; INTERFERON-BETA; PHOSPHORYLATION; PROTEIN TRANSPORT; RECOMBINANT PROTEINS; SMAD2 PROTEIN; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878017503     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28072     Document Type: Article

References (29)

1. Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208: 1989-2003.
2. Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011; 208: 2005-16.
3. Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-15.
4. Reizis B, Bunin A, Ghosh HS, et al. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol 2011; 29: 163-83.
5. Gilliet M, Cao W, Liu YJ,. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8: 594-606.
6. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772-7.
7. Hartmann E, Wollenberg B, Rothenfusser S, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63: 6478-87.
8. Labidi-Galy SI, Sisirak V, Meeus P, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 71: 5423-34.
9. Labidi-Galy SI, Treilleux I., Goddard-Leon S, et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. OncoImmunology 2012; 1: 380-2.
10. Treilleux I, Blay JY, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10: 7466-74.
11. Sisirak V, Faget J, Gobert M, et al. Impaired IFN-a production by plasmacytoid dendritic cells favors regulatory T cell expansion and may contribute to breast cancer progression. Cancer Res 2012; 72: 5188-97.
12. Jensen TO, Schmidt H, Moller HJ, et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012; 118: 2476-85.
13. Bekeredjian-Ding I, Schafer M, Hartmann E, et al. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology 2009; 128: 439-50.
14. Ma Y, Aymeric L, Locher C, et al. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 2011; 23: 146-52.
15. Thomachot MC, Bendriss-Vermare N, Massacrier C, et al. Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes. Int J Cancer 2004; 110: 710-20.
16. Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005; 102: 3372-7.
17. Contractor N, Louten J, Kim L, et al. Cutting edge: Peyer's patch plasmacytoid dendritic cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGFbeta, and prostaglandin E2 in conditioning a unique mucosal pDC phenotype. J Immunol 2007; 179: 2690-4.
18. Li L, Liu S, Zhang T, et al. Splenic stromal microenvironment negatively regulates virus-activated plasmacytoid dendritic cells through TGF-{beta}. J Immunol 2008; 180: 2951-6.
19. Domschke C, Schuetz F, Ge Y, et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009; 69: 8420-8.
20. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.
21. O'Keeffe M, Grumont RJ, Hochrein H, et al. Distinct roles for the NF-kappaB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals. Blood 2005; 106: 3457-64.
22. Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009; 206: 1983-94.
23. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-9.
24. Heilborn JD, Nilsson MF, Jimenez CI, et al. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer 2005; 114: 713-9.
25. Shi Y, Evans JE, Rock KL,. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-21.
26. Quidville V, Conforti R, Zoubir M, et al. Lymphocyte infiltration and interferon response to predict efficacy of anthracyclines [abstract]. Ann Oncol 2009; 20: 56.
27. Hennessy EJ, Parker AE, O'Neill LA,. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9: 293-307.
28. Kelly RJ, Morris JC,. Transforming growth factor-beta: a target for cancer therapy. J Immunotoxicol 2010; 7: 15-26.
29. Drobits B, Holcmann M, Amberg N, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122: 575-85.